1. Home
  2. GANX vs SWVL Comparison

GANX vs SWVL Comparison

Compare GANX & SWVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • SWVL
  • Stock Information
  • Founded
  • GANX 2017
  • SWVL 2017
  • Country
  • GANX United States
  • SWVL United Arab Emirates
  • Employees
  • GANX N/A
  • SWVL N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • SWVL Business Services
  • Sector
  • GANX Health Care
  • SWVL Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • SWVL Nasdaq
  • Market Cap
  • GANX 57.9M
  • SWVL 50.6M
  • IPO Year
  • GANX 2021
  • SWVL N/A
  • Fundamental
  • Price
  • GANX $1.93
  • SWVL $4.83
  • Analyst Decision
  • GANX Strong Buy
  • SWVL
  • Analyst Count
  • GANX 5
  • SWVL 0
  • Target Price
  • GANX $8.20
  • SWVL N/A
  • AVG Volume (30 Days)
  • GANX 226.2K
  • SWVL 21.2K
  • Earning Date
  • GANX 05-14-2025
  • SWVL 06-10-2025
  • Dividend Yield
  • GANX N/A
  • SWVL N/A
  • EPS Growth
  • GANX N/A
  • SWVL N/A
  • EPS
  • GANX N/A
  • SWVL N/A
  • Revenue
  • GANX N/A
  • SWVL $17,207,362.00
  • Revenue This Year
  • GANX N/A
  • SWVL N/A
  • Revenue Next Year
  • GANX N/A
  • SWVL N/A
  • P/E Ratio
  • GANX N/A
  • SWVL N/A
  • Revenue Growth
  • GANX N/A
  • SWVL N/A
  • 52 Week Low
  • GANX $0.89
  • SWVL $2.40
  • 52 Week High
  • GANX $3.19
  • SWVL $10.87
  • Technical
  • Relative Strength Index (RSI)
  • GANX 53.25
  • SWVL 67.94
  • Support Level
  • GANX $1.80
  • SWVL $4.51
  • Resistance Level
  • GANX $1.85
  • SWVL $4.89
  • Average True Range (ATR)
  • GANX 0.13
  • SWVL 0.44
  • MACD
  • GANX -0.00
  • SWVL 0.06
  • Stochastic Oscillator
  • GANX 60.00
  • SWVL 91.79

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About SWVL Swvl Holdings Corp

Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. Its technology and services provide commuters, travelers and businesses with an alternative to traditional public transportation, taxi companies or other ridesharing companies. The company's core product is B2C Swvl Retail offering, which provides riders with a network of minibuses and other vehicles running on fixed or semi-fixed routes within cities. Commuters use its Swvl mobile application to book rides between pre-defined pick-up points located throughout the city.

Share on Social Networks: